课题基金 / 基金详情

Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis

Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
脓毒症后 CD4 T 细胞依赖性 B 细胞反应的受损和恢复
批准号:
10084212
负责人:
Thomas S Griffith
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-10-01 至 2021-12-31

项目摘要

项目成果

Thomas S Griffith的其他基金

相似基金

相关文献

中文摘要
翻译
败血症每年在美国医院造成的死亡人数超过前列腺癌,乳腺癌和艾滋病 加起来老年患者是一个特别高危的群体,其发病率约占所有脓毒症病例的60%。 老年人也极易受到脓毒症后果的影响,死亡率高出100倍 比年轻的病人。这些死亡中的一些发生在脓毒症后急性,但这些患者中约70%的人在感染后存活。 初始感染,并在脓毒症的慢性阶段死于机会性感染。慢性期 脓毒症的发生是重要的,其特征是免疫抑制,但对脓毒症的机制知之甚少。 脓毒症引起的免疫抑制 对于协调针对一系列病原体的免疫反应至关重要的CD 4 T细胞严重耗竭 在脓毒症的急性期,并在脓毒症的免疫抑制期逐渐恢复。 我们最近的出版物包括显示某些Ag特异性CD 4 T细胞群不能恢复的数据, 尽管总的CD 4 T细胞定量恢复。我们怀疑Ag-特异性CD 4 T细胞的长期丢失可能是由于 细胞在T细胞库中引入“缺口”,导致适应性免疫系统的整体下降。 功能在CD 4 T细胞功能至关重要的免疫学环境中,该提案将定义CD 4 T细胞的功能。 使用CLP模型研究CD 4 T细胞依赖性B细胞应答受损的机制 随后进行二次免疫或异源病原体感染。因此,我们的中心假设 认为,滤泡辅助性CD 4 T(Tfh)细胞和B细胞的数量和功能的改变, 亚致死性CLP诱导的脓毒症是抑制体液免疫和降低抗 在局部或全身继发感染的背景下遇到的病原体。 以下具体目的将检验我们的假设:目的1)定义脓毒症诱导的Ag特异性缺陷 限制产生生产性CD 4 T细胞依赖性B细胞应答的CD 4 T细胞和B细胞;目的 2)研究旨在恢复DC或B细胞数量和功能的治疗方法, 脓毒症后的免疫;和目的3)确定脓毒症对前- 现有的记忆性CD 4 T细胞和B细胞。最终,这一建议将增加我们对为什么 败血症患者更容易继发感染。我们使用CLP多微生物败血症模型, 我们鉴定和研究内源性Ag特异性CD 4 T细胞和B细胞功能的能力,以及我们 测量对传染性病原体的适应性免疫反应的经验使我们处于完美的位置, 定义驱动脓毒症诱导的CD 4 T细胞依赖性B细胞免疫抑制的机制。
英文摘要
Sepsis causes more deaths in U.S. hospitals annually than prostate cancer, breast cancer, and AIDS combined. Elderly patients are a particularly high-risk group, with an incidence rate of ~60% of all septic cases. The elderly are also extremely vulnerable to the consequences of sepsis, showing 100-fold higher mortality than younger patients. Some of these deaths occur acutely after sepsis, but ~70% of these patients survive the initial infection, and succumb to opportunistic infections during the chronic phase of sepsis. The chronic stage of sepsis is important and is characterized by immunosuppression, but little is known about the mechanisms of sepsis-induced immunosuppression. CD4 T cells, essential for coordinating immune responses to a range of pathogens, are severely depleted during the acute stage of sepsis, and gradually recover throughout the immunosuppressive phase of sepsis. Our recent publication included data showing certain Ag-specific CD4 T cell populations do not recover, despite quantitative restoration of total CD4 T cells. We suspect that the prolonged loss of Ag-specific CD4 T cells introduces “gaps” within the T cell repertoire leading to overall decreased adaptive immune system function. Among the immunological settings where CD4 T cell function is vital, this proposal will define the mechanisms responsible for the impairment of CD4 T cell-dependent B cell responses using the CLP model followed by secondary immunization or heterologous pathogen infection. Accordingly, our central hypothesis holds that alterations in the number and function of both follicular helper CD4 T (Tfh) cells and B cells after sublethal CLP-induced sepsis is responsible for suppressed humoral immunity and reduced protection against pathogens encountered within the context of localized or systemic secondary infections. The following specific aims will test our hypothesis: Aim 1) Define the sepsis-induced defects in Ag-specific CD4 T cells and B cells that restrict the generation of a productive CD4 T cell-dependent B cell response; Aim 2) Investigate the ability of therapies designed to restore DC or B cell number and function to revitalize humoral immunity after sepsis; and Aim 3) Determine the impact of sepsis on the maintenance and function of pre- existing memory CD4 T cells and B cells. Ultimately, this proposal will increase our understanding of why septic patients are more susceptible to secondary infections. Our use of the CLP model of polymicrobial sepsis, our ability to identify and study the function of endogenous Ag-specific CD4 T cells and B cells, and our experience measuring the adaptive immune response to infectious pathogens put us in the perfect position to define the mechanism(s) driving sepsis-induced suppression of CD4 T cell-dependent B cell immunity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BLRD Research Career Scientist Award Application
  • 批准号:
    10582394
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2023
  • 负责人:
    Thomas S Griffith
  • 依托单位:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
  • 批准号:
    10257687
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    2021
  • 负责人:
    Thomas S Griffith
  • 依托单位:
CD4 T cell dysfunction and reprogramming during sepsis
  • 批准号:
    10633073
  • 项目类别:
  • 资助金额:
    $38.75万
  • 财政年份:
    2021
  • 负责人:
    Thomas S Griffith
  • 依托单位:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
  • 批准号:
    10413143
  • 项目类别:
  • 资助金额:
    $19.38万
  • 财政年份:
    2021
  • 负责人:
    Thomas S Griffith
  • 依托单位:
海外基金